Across TCGA pan-cancer cohorts, RNU6-1056P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNU6-1056P’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RNU6-1056P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-1056P is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

BLCA, KIRC, and BRCA are the cancer types where RNU6-1056P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1056P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.283	.011	5	view →
KIRC	Male	All	+0.084	.020	5	view →
BRCA	All	III,IV	−0.148	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RNU6-1056P RNA expression & survival · all RNU6-1056P data types